Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Workload, Job Satisfaction and Quality of Nursing Care in Italy: A Systematic Review of Native Language Articles.
Serra N, Botti S, Guillari A, Simeone S, Latina R, Iacorossi L, Torreggiani M, Guberti M, Cicolini G, Lupo R, Capuano A, Pucciarelli G, Gargiulo G, Tomietto M, Rea T. Serra N, et al. Among authors: torreggiani m. Healthcare (Basel). 2023 Sep 18;11(18):2573. doi: 10.3390/healthcare11182573. Healthcare (Basel). 2023. PMID: 37761770 Free PMC article. Review.
Patient-reported outcome measure to implement routine assessment of cancer survivors' unmet needs: An overview of reviews and COSMIN analysis.
Contri A, Paltrinieri S, Torreggiani M, Chiara Bassi M, Mazzini E, Guberti M, Campanini I, Ghirotto L, Fugazzaro S, Costi S. Contri A, et al. Among authors: torreggiani m. Cancer Treat Rev. 2023 Nov;120:102622. doi: 10.1016/j.ctrv.2023.102622. Epub 2023 Sep 9. Cancer Treat Rev. 2023. PMID: 37713972 Free article. Review.
Hypertension and Proteinuria in a Pregnancy: A Quiz.
Torreggiani M, Stancanelli MR, Njandjo L, Fois A, Piccoli GB. Torreggiani M, et al. Am J Kidney Dis. 2024 May;83(5):A17-A18. doi: 10.1053/j.ajkd.2023.10.019. Am J Kidney Dis. 2024. PMID: 38643986 No abstract available.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Roadmaps to green nephrology: a mediterranean point of view.
Ben Hmida M, Torreggiani M, Berman-Parks N, Salomone M, Piccoli GB. Ben Hmida M, et al. Among authors: torreggiani m. Curr Opin Nephrol Hypertens. 2024 Jan 1;33(1):115-121. doi: 10.1097/MNH.0000000000000943. Epub 2023 Nov 2. Curr Opin Nephrol Hypertens. 2024. PMID: 37916609 Review.
98 results